Dergiler / Uluslararası Hematoloji-Onkoloji Dergisi / 2020 / Cilt: 30 - Sayı: 3

Intravenous Chemotherapy Adherence of Cancer Patients in Time of Covid-19 Crisis

Sayfa
133–138
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In the case of pandemic regulations, oncologic patients may have special considerations for government decisions.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:SARS-CoV-2 is a single-stranded RNA spherical virus spikes formed by glycoproteins.
📊
Temel Bulgular & Veri:After the first case reported on the 11th of March in Turkey Ministry of Health and Interior declared some regulations on the public, such as travel restrictions, traffic restrictions, social distancing homes, and centralized quarantine.
💡
Sonuç & Katkı:In the case of pandemic regulations, oncologic patients may have special considerations for government decisions.
🔬Tür:Araştırma Makalesi
📍Kapsam:2020 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

SARS-CoV-2 is a single-stranded RNA spherical virus spikes formed by glycoproteins. The leading cause of death was linked to acute respiratory distress syndrome, myocardial injury, or renal failure. After the first case reported on the 11th of March in Turkey Ministry of Health and Interior declared some regulations on the public, such as travel restrictions, traffic restrictions, social distancing homes, and centralized quarantine. Although chemotherapy adherence is a highly studied area for both oral and intravenous agents in cancer patients, no available data exist in a pandemic world with many social restrictions. The records of patients who have active cancer treatment in the department of medical oncology retrospectively analyzed. The age, gender, diagnosis, chemotherapy type, rendezvous, and coming dates recorded. Four chemotherapy delays (3.7%) were observed out of 52 patients before the 11th of March 2020, while 43 chemotherapy delays (39,8%9) occurred out of 107 patients after the first COVID-19 case and the restrictions in Turkey. Twenty patients had treatment delay without reason and did not show up for treatment on the day of chemotherapy. The treatment delays without reasons are significantly different in the pre and post COVID-19 pandemic era. The hematologic toxicity rates were similar when compared pre and post COVID-19 period. The non-specific regulations and declarations confuse the patients and prevent them from reaching the treatment which is needed. In the case of pandemic regulations, oncologic patients may have special considerations for government decisions.

🔖

Bu Makaleye Atıf Yap

BEYPINAR, İ., URUN, M. (2020). Intravenous Chemotherapy Adherence of Cancer Patients in Time of Covid-19 Crisis. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 30 - Sayı: 3, 133–138. https://ajindex.com/articles/322734

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Wassenaar TM, Zou Y. 2019_nCoV/SARS-CoV-2: rapid classification of betacoronaviruses and identification of Traditional Chinese Medicine as potential origin of zoonotic coronaviruses. Lett Appl Microbiol 70: 342-348, 2020
  2. Gorbalenya A, Baker S, Baric R, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. Nat Microbiol [Internet] 2020;2020.02.07.937862. Available from: http:// biorxiv.org/content/early/2020/02/11/2020.02.07.937862. abstract 3. Benvenuto D, Giovanetti M, Ciccozzi A, et al. The 2019-new coronavirus epidemic: Evidence for virus evolution. J Med Virol 92: 455-459, 2020
  3. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395: 565-574, 2020
  4. Jiang F, Deng L, Zhang L, et al. Review of the clinical characteristics of Coronavirus disease 2019 (COVID-19). J Gen Intern Med 35: 1545-1549, 2020
  5. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395: 507-513, 2020
  6. Xia Y, Jin R, Zhao J, et al. Risk of COVID-19 for patients with cancer. Lancet Oncol 21(4): e180, 2020
  7. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol 21(4): e181, 2020
  8. Russell B, Moss C, George G, et al. Associations between immune-suppressive and stimulating drugs and novel COVID- 19 - A systematic review of current evidence. Ecancermedicalscience 14: 1022, 2020
  9. Benites ECA, Cabrini DP, Silva ACB, et al. Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy. J Pediatr (Rio J) 90: 370-376, 2014
  10. Nilsson A, Edner N, Albert J, Ternhag A. Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child. Infect Dis (Auckl) 52: 419-422, 2020
  11. Folz RJ, Elkordy MA. Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer. Chest 115: 901-905, 1999
  12. Livingston E, Bucher K, Rekito A. Coronavirus disease 2019 and Influenza 2019-2020 [Internet]. JAMA - J Am Med Assoc 323: 1122, 2020
  13. Thomson DJ, Palma D, Guckenberger M, et al. Practice recommendations for risk-adapted head and neck cancer Radiation therapy during the COVID-19 Pandemic: An ASTROESTRO Consensus Statement. Int J Radiat Oncol Biol Phys 107: 618-627, 2020
  14. Mohile NA, Blakeley JO, Gats